<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations of antiphospholipid syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations of antiphospholipid syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations of antiphospholipid syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Doruk Erkan, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stéphane Zuily, MD, MPH, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Pisetsky, MD, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Antiphospholipid syndrome (APS) is an autoimmune multisystem disorder characterized by arterial, venous, or small vessel thromboembolic events and/or pregnancy morbidity in the presence of persistent antiphospholipid antibodies (aPL) [<a href="#rid1">1</a>]. aPLs are a heterogenous group of autoantibodies which are directed against phospholipid-binding proteins.</p><p>APS occurs as a primary condition or in the setting of an underlying systemic autoimmune disease, particularly systemic lupus erythematosus (SLE).</p><p>The clinical manifestations of APS will be reviewed here. Pathogenesis, diagnosis, and treatment of APS are presented separately. (See  <a class="medical medical_review" href="/d/html/4676.html" rel="external">"Pathogenesis of antiphospholipid syndrome"</a> and  <a class="medical medical_review" href="/d/html/4678.html" rel="external">"Diagnosis of antiphospholipid syndrome"</a> and  <a class="medical medical_review" href="/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome"</a>.)</p><p>Catastrophic APS (CAPS) and kidney manifestations of APS are discussed separately. (See  <a class="medical medical_review" href="/d/html/106168.html" rel="external">"Catastrophic antiphospholipid syndrome (CAPS)"</a> and  <a class="medical medical_review" href="/d/html/3073.html" rel="external">"Antiphospholipid syndrome and the kidney"</a>.)</p><p class="headingAnchor" id="H185750669"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>In a large retrospective analysis including patients without known autoimmune diseases, antiphospholipid antibodies (aPL) were present in approximately 9 percent of patients with pregnancy losses, 14 percent with stroke, 11 percent with myocardial infarction (MI), and 10 percent with deep vein thrombosis (DVT) [<a href="#rid2">2</a>].</p><p>Estimates in the United States suggest that aPL are associated with approximately 50,000 pregnancy losses, 110,000 strokes, 100,000 MIs, and 30,000 DVTs annually [<a href="#rid2">2-8</a>]. Epidemiologic studies done in the general population from the United States and Italy determined a prevalence of antiphospholipid syndrome (APS) ranging from 17 to 50 patients per 100,000 [<a href="#rid9">9,10</a>].</p><p class="headingAnchor" id="H86593088"><span class="h1">PRIMARY APS VERSUS APS WITH SLE</span><span class="headingEndMark"> — </span>Approximately half of patients with antiphospholipid syndrome (APS) have primary disease, while the other half have a concomitant systemic autoimmune disease. Systemic lupus erythematosus (SLE) is the disease most commonly associated with APS, which is present in approximately 35 percent of cases [<a href="#rid11">11</a>].</p><p>Although many of the clinical manifestations of primary APS and APS associated with SLE are similar [<a href="#rid12">12</a>], patients with SLE-associated APS are more likely to have arthritis, livedo reticularis, heart valve disease, thrombocytopenia, and leukopenia than patients with primary APS [<a href="#rid13">13-15</a>]. Another study found that the frequencies of arterial thrombosis, venous thrombosis, and fetal loss were greater in patients with APS and SLE than in those with primary APS [<a href="#rid16">16</a>]. However, traditional cardiovascular risk factors and markers of early atherosclerosis are similar between patients with primary and SLE-associated APS [<a href="#rid17">17,18</a>]. </p><p>A separate issue regarding the relationship of APS and SLE is the frequency of evolution of APS into SLE or lupus-like disease. Three studies involving 70 to 128 patients with APS found a variable rate of development of SLE over time:</p><p class="bulletIndent1"><span class="glyph">●</span>0 percent at 5 years [<a href="#rid19">19</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>4 percent at 6.5 years [<a href="#rid20">20</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>13 to 23 percent at 9 years [<a href="#rid21">21,22</a>]</p><p></p><p class="headingAnchor" id="H10"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>In addition to the hallmark features of venous, arterial, and/or small vessel thrombosis as well as specific pregnancy complications, other relatively common clinical features of antiphospholipid syndrome (APS) include livedo reticularis, thrombocytopenia, or transient ischemic attack [<a href="#rid23">23</a>].</p><p>Rarely, patients with APS can develop catastrophic APS (CAPS), with widespread thrombotic disease and multiorgan failure  (<a class="graphic graphic_table graphicRef62724" href="/d/graphic/62724.html" rel="external">table 1</a>). CAPS can also rarely be the initial presentation of APS. (See  <a class="medical medical_review" href="/d/html/106168.html" rel="external">"Catastrophic antiphospholipid syndrome (CAPS)"</a>.)</p><p>In a series of 1000 patients with either primary or autoimmune disease-associated APS, the various disease features were [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Deep vein thrombosis (DVT) – 32 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia – 22 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Livedo reticularis – 20 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Stroke – 13 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Superficial thrombophlebitis – 9 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary embolism – 9 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Fetal loss – 8 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Transient ischemic attack – 7 percent</p><p></p><p>Several studies have identified that particular combinations of features are seen more often together or in a given patient over time (eg, stroke and valvular heart disease, livedo and arterial thrombosis, thrombocytopenia and small vessel thrombosis). A cluster analysis demonstrated that small vessel thrombosis and pregnancy morbidity manifestations were found in patients with non-criteria manifestations [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/4678.html" rel="external">"Diagnosis of antiphospholipid syndrome", section on 'Classification criteria'</a>.)</p><p>In addition to those manifestations mentioned above, some of the other possible antiphospholipid antibody (aPL)-related clinical manifestations include cardiac valve disease, pulmonary hypertension, thrombocytopenia, cutaneous ulcers and adrenal insufficiency due to hemorrhagic infarction, and cognitive deficits [<a href="#rid23">23,24,26-29</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Thrombotic events</span><span class="headingEndMark"> — </span>Thromboses are the hallmark of APS, and venous thromboses are more common than arterial thromboses [<a href="#rid24">24</a>]. The risk of both venous and arterial thrombosis and/or thromboembolism is increased in individuals with positive tests for lupus anticoagulant (LA) activity (odds ratio [OR] 11) or with medium or high levels of anticardiolipin antibodies (aCL; OR 1.6) [<a href="#rid30">30</a>]. The risk of recurrent thrombosis or thromboembolism may be further enhanced in those with positivity to three aPL, also known as "triple positivity," (LA, aCL, and anti-beta2 glycoprotein [GP] I antibodies) upon repeated testing [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H61739457"><span class="h3">Venous thrombosis</span><span class="headingEndMark"> — </span>The deep veins of the lower extremities are the most common sites of thrombosis, with estimates from large cohort studies ranging from 20 to 30 percent of patients with APS [<a href="#rid24">24,32</a>]. Other sites of venous thrombosis include the pelvic, renal, pulmonary, hepatic, portal, axillary, subclavian, ocular, and cerebral sinuses, as well as the inferior vena cava. Superficial vein thrombosis can also occur [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H61739469"><span class="h3">Arterial thrombosis</span><span class="headingEndMark"> — </span>The most common site of arterial thrombosis is in the cerebral vasculature, usually in the form of a stroke or transient ischemic attack [<a href="#rid24">24</a>]. Occlusions in the retinal, coronary, renal, and mesenteric arteries can also occur. Stroke in patients with APS is discussed in further detail below. (See <a class="local">'Neurologic involvement'</a> below.)</p><p class="headingAnchor" id="H66251939"><span class="h3">Recurrent thrombotic events</span><span class="headingEndMark"> — </span>The recurrence rate of thrombotic events among patients with APS is highly variable among studies, with an annual recurrent thrombosis risk ranging from 5 to 12 percent [<a href="#rid11">11,31,33-36</a>]. In patients after a first unprovoked venous thromboembolism (VTE) for which the anticoagulation was stopped, the annual risk of recurrent VTE can be much higher, ranging from 10 to 20 percent [<a href="#rid37">37</a>]. The presence of LA or triple aPL positivity is the main risk factors for recurrence [<a href="#rid31">31,36,38,39</a>].</p><p>Most, but not all, studies have indicated that an initial arterial thrombosis tends to be followed by an arterial event and that an initial venous thrombosis is usually followed by a venous event [<a href="#rid40">40-42</a>]. In a report in which 186 recurrences occurred in 101 patients, the site of recurrence was arterial in 93 percent of those with an initial arterial thrombosis, and the site of recurrence was venous in 76 percent of those with an initial venous thrombosis [<a href="#rid42">42</a>]. The factors that determine the predilection for the venous or arterial circulation are not known.</p><p class="headingAnchor" id="H15"><span class="h2">Neurologic involvement</span><span class="headingEndMark"> — </span>Central nervous system abnormalities are a common feature of APS that have been attributed to both vascular thrombosis as well as direct injury to neuronal tissue by aPL [<a href="#rid43">43</a>]. Stroke and transient ischemic attack are the most common neurologic manifestations of APS. A thrombotic stroke occurring in a young patient with no overt risk factors for cerebrovascular disease is a classic setting in which to suspect APS [<a href="#rid2">2</a>].</p><p>Ischemic stroke may be a manifestation in situ thrombosis or due to embolism arising from valvular heart disease. If routine transthoracic echocardiography is normal, transesophageal echocardiography may be indicated to assess for vegetations due to nonbacterial endocarditis. (See <a class="local">'Cardiac involvement'</a> below.)</p><p>Sneddon syndrome, which is characterized by widespread livedo reticularis in association with a stroke, has also been described among patients with aPL [<a href="#rid44">44,45</a>]. In almost half of all cases, Sneddon syndrome is associated with detectable aPL [<a href="#rid44">44</a>].</p><p>Cognitive deficits independent of stroke and/or white matter lesions have been associated with APS [<a href="#rid46">46,47</a>]. The degree of reported cognitive deficits ranges from subtle findings to transient global amnesia to permanent and profound cognitive functioning. The cognitive deficits reported in APS are sometimes but not always associated with white matter lesions. As an example, cognitive deficits were evaluated in a study of 60 patients with primary or secondary APS who underwent comprehensive neuropsychological testing [<a href="#rid26">26</a>]. The APS patients were compared with 60 healthy controls, matched for age, sex, and education, and 25 disease controls (systemic lupus erythematosus [SLE] and rheumatoid arthritis patients who did not have APS). The following observations were made:</p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive deficits were significantly more frequent in the patients with APS (42 versus 18 and 16 percent of the healthy and disease controls, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive dysfunction in the APS patients was associated with livedo reticularis on physical examination and with the finding of white matter lesions on brain magnetic resonance imaging (MRI).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No relationship was detected between cognitive dysfunction and previous central nervous system disease (eg, stroke).</p><p></p><p>Multifocal white matter lesions on MRI that are suggestive of a vasculopathy are a common finding on MRI in APS patients [<a href="#rid26">26</a>]. These lesions may be difficult to distinguish from those in multiple sclerosis [<a href="#rid48">48,49</a>].</p><p>Other less common neurologic disorders that have been reported in aPL-positive patients include epilepsy, psychosis, chorea, and hemiballismus, transverse myelopathy, sensorineural hearing loss, and migraine [<a href="#rid24">24,26,50-60</a>]. However, no strong association has been established between these manifestations and aPL.</p><p class="headingAnchor" id="H21"><span class="h2">Hematologic abnormalities</span><span class="headingEndMark"> — </span>Thrombocytopenia can be observed in APS patients and is discussed further below (see <a class="local">'Thrombocytopenia'</a> below). Other hematologic abnormalities reported in patients with APS include autoimmune hemolytic anemia, especially if there is widespread thrombosis; and various thrombotic microangiopathic syndromes including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) [<a href="#rid61">61</a>]. (See <a class="local">'Other'</a> below and  <a class="medical medical_review" href="/d/html/4434.html" rel="external">"Evaluation of bone marrow aspirate smears", section on 'Bone marrow necrosis'</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Pulmonary involvement</span><span class="headingEndMark"> — </span>Patients with APS may develop various lung manifestations including pulmonary thromboembolic disease, thromboembolic and non-thromboembolic pulmonary hypertension (pulmonary arterial hypertension [<a href="#rid62">62,63</a>]), pulmonary arterial thrombosis, pulmonary microthrombosis, acute respiratory distress syndrome, and diffuse alveolar hemorrhage [<a href="#rid24">24,64-69</a>]. (See  <a class="medical medical_review" href="/d/html/4341.html" rel="external">"The diffuse alveolar hemorrhage syndromes"</a> and  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"</a> and  <a class="medical medical_review" href="/d/html/8254.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension"</a>.)</p><p class="headingAnchor" id="H26"><span class="h2">Cardiac involvement</span><span class="headingEndMark"> — </span>Cardiac manifestations of APS most commonly involve the valves, including valvular thickening and valve nodules (also referred to as nonbacterial vegetations or Libman-Sacks endocarditis)  (<a class="graphic graphic_picture graphicRef79709" href="/d/graphic/79709.html" rel="external">picture 1</a>) [<a href="#rid24">24,70-75</a>]. The mitral valve is most frequently involved, followed by the aortic valve [<a href="#rid76">76</a>]. Involvement of the mitral and aortic valves can lead to valvular regurgitation and, rarely, to stenosis [<a href="#rid73">73-75</a>]. Valve lesions, especially aortic nodules, are highly associated with the risk of stroke [<a href="#rid77">77,78</a>]. The risk of heart valve disease is higher in patients with LA or immunoglobulin G (IgG) aCL (OR 6) than those with IgM aCL (OR 3) [<a href="#rid79">79</a>].</p><p>Patients with APS also have an increased risk for developing coronary artery disease. Myocardial infarction may be due to coronary thromboembolism, accelerated atherosclerosis leading to a plaque rupture, or microvascular thrombosis (detected by MRI) with a normal coronary vascular bed [<a href="#rid70">70</a>]. One study found that aPL (including lupus anticoagulant and anticardiolipin anti-beta 2 glycoprotein (GP) 1 antibodies) was associated with a twofold increased risk of myocardial infarction [<a href="#rid80">80</a>].</p><p class="headingAnchor" id="H30"><span class="h2">Cutaneous manifestations</span><span class="headingEndMark"> — </span>APS has been associated with many cutaneous abnormalities including splinter hemorrhages, livedo reticularis and racemosa  (<a class="graphic graphic_picture graphicRef67495" href="/d/graphic/67495.html" rel="external">picture 2</a>), cutaneous necrosis and infarction, digital gangrene, skin ulcerations, lesions resembling vasculitis ("pseudovasculitic" nodules, macules), and livedoid vasculopathy (with/without atrophie blanche) [<a href="#rid1">1,24,81-84</a>]. (See  <a class="medical medical_review" href="/d/html/4684.html" rel="external">"Livedoid vasculopathy"</a>.)</p><p>Livedo is the most common cutaneous manifestation of APS. Although livedo reticularis is nonspecific, livedo racemosa can be associated with arterial lesions and multiple thromboses in APS [<a href="#rid85">85</a>]. Livedo is present in more than 20 percent of SLE patients with aPL compared with 10 percent in SLE patients without aPL. In the general population, prevalence of livedo is lower than in patients with SLE [<a href="#rid86">86</a>]. In a series of 200 patients with APS, livedo reticularis was associated with cerebral or ocular ischemic events (OR 10.8) [<a href="#rid82">82</a>]. By contrast, livedo reticularis was observed with decreased frequency in patients who experienced only venous thromboses (OR 0.2).</p><p>There is considerable ambiguity in the literature with regard to the terms "livedo reticularis" and "livedo racemosa" [<a href="#rid87">87</a>]. Livedo racemosa is characterized by a violaceous net-like pattern on the skin with irregular and/or broken circles; livedo reticularis is characterized by unbroken circles [<a href="#rid88">88</a>]. Livedo racemosa, named by Ehrmann in 1907 [<a href="#rid89">89</a>], is a more striking cutaneous finding than livedo reticularis [<a href="#rid87">87</a>]. In addition, livedo reticularis often occurs in physiologic settings rather than in disease states [<a href="#rid90">90</a>]. The clinical significance of differentiating between livedo racemosa and livedo reticularis was illustrated in a study of 111 patients with livedo racemosa and 32 patients with livedo reticularis [<a href="#rid88">88</a>]. The former were more likely to have biopsy-proven cutaneous vasculitis; to be younger and male; and to have arthralgia, higher levels of C-reactive protein (CRP), and antibodies to phosphatidylserine prothrombin complexes. (See  <a class="medical medical_review" href="/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Vascular abnormalities'</a> and  <a class="medical medical_review" href="/d/html/7543.html" rel="external">"Clinical manifestations and diagnosis of Raynaud phenomenon", section on 'Signs and symptoms of Raynaud phenomenon'</a>.)</p><p>As mentioned above, livedo reticularis in association with stroke is known as Sneddon syndrome, and half of the time occurs in the presence of aPL. (See <a class="local">'Neurologic involvement'</a> above.)</p><p class="headingAnchor" id="H32"><span class="h2">Kidney disease</span><span class="headingEndMark"> — </span>Kidney disease occurs in a minority of patients with primary APS. Glomerular capillaries and other renal vessels, both arteries and veins of all sizes, can be affected. The disease may be silent or may produce acute or chronic kidney failure with proteinuria and hypertension. A detailed discussion of kidney involvement in patients with APS, including those with underlying SLE, is presented separately. (See  <a class="medical medical_review" href="/d/html/3073.html" rel="external">"Antiphospholipid syndrome and the kidney"</a>.)</p><p class="headingAnchor" id="H33"><span class="h2">Gastrointestinal involvement</span><span class="headingEndMark"> — </span>Patients with APS may have ischemia involving the esophagus, stomach, duodenum, jejunum, ileum, or colon resulting in gastrointestinal bleeding, abdominal pain, an acute abdomen, esophageal necrosis with perforation, or giant gastric or atypical duodenal ulceration [<a href="#rid91">91</a>]. Splenic or pancreatic infarction may also occur [<a href="#rid24">24</a>]. In addition, the liver may be involved; hepatic or portal venous thrombosis may result in the Budd-Chiari syndrome, hepatic-veno-occlusive disease, hepatic infarction, portal hypertension, and cirrhosis [<a href="#rid91">91,92</a>].</p><p class="headingAnchor" id="H34"><span class="h2">Ocular involvement</span><span class="headingEndMark"> — </span>Amaurosis fugax, retinal venous [<a href="#rid93">93</a>] and arterial occlusion, and anterior ischemic optic neuropathy have occurred in patients with aPL [<a href="#rid24">24,94,95</a>].</p><p class="headingAnchor" id="H35"><span class="h2">Adrenal disease</span><span class="headingEndMark"> — </span>Loss of adrenal function due to bilateral adrenal vein thrombosis, resulting in hemorrhagic infarction, may occur in association with APS, especially catastrophic APS [<a href="#rid96">96,97</a>]. An enlarged adrenal or an adjacent mass may be apparent on a computed tomography (CT) scan, but MRI is more effective in determining the age of adrenal hemorrhage and in differentiating bleeding from other causes of adrenal gland enlargement. Adrenal hemorrhagic infarction may present as abdominal, lumbar, pelvic, or thoracic pain. (See  <a class="medical medical_review" href="/d/html/166.html" rel="external">"Causes of primary adrenal insufficiency (Addison disease)", section on 'Hemorrhagic infarction'</a>.)</p><p>Adrenal involvement can also be seen in CAPS. (See  <a class="medical medical_review" href="/d/html/106168.html" rel="external">"Catastrophic antiphospholipid syndrome (CAPS)", section on 'Thrombosis and organ involvement'</a>.)</p><p class="headingAnchor" id="H36"><span class="h2">Osteonecrosis</span><span class="headingEndMark"> — </span>Asymptomatic changes in the appearance of the femoral heads of patients with primary APS have been noted on MRI. These findings have been interpreted to indicate osteonecrosis. However, of the 30 patients who were the subject of one report, none had changes on plain radiographs, and none had progressive changes on subsequent MRIs [<a href="#rid98">98</a>]. Thus, the true nature of the association between osteonecrosis and the presence of APS is not clear.</p><p class="headingAnchor" id="H304588518"><span class="h1">PREGNANCY COMPLICATIONS</span><span class="headingEndMark"> — </span>In addition to thrombotic events, pregnancy complications are the other hallmark of antiphospholipid syndrome (APS). These complications include fetal death after 10 weeks gestation, premature birth due to severe preeclampsia or placental insufficiency, or embryonic losses (&lt;10 weeks gestation). Fetal loss in patients with aPL and the approach to women with recurrent fetal loss are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6813.html" rel="external">"Antiphospholipid syndrome: Obstetric implications and management in pregnancy"</a> and  <a class="medical medical_review" href="/d/html/5436.html" rel="external">"Recurrent pregnancy loss: Evaluation"</a>.)</p><p>In aPL-positive patients with preeclampsia or the HELLP Syndrome (hemolysis, elevated liver enzymes, and low platelet count in association with pregnancy), the possibility of the evolving catastrophic APS (CAPS) must be considered, particularly in patients with histories of thrombosis or spontaneous abortions [<a href="#rid99">99,100</a>]. (See  <a class="medical medical_review" href="/d/html/6778.html" rel="external">"HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)"</a> and  <a class="medical medical_review" href="/d/html/106168.html" rel="external">"Catastrophic antiphospholipid syndrome (CAPS)", section on 'When to suspect'</a>.)</p><p class="headingAnchor" id="H996304054"><span class="h1">LABORATORY FINDINGS</span><span class="headingEndMark"> — </span>In addition to the presence of antiphospholipid antibodies (aPL), some of the other potential laboratory findings include thrombocytopenia, hemolytic anemia, prolonged activated partial thromboplastin time (aPTT), a history of a false-positive serologic test for syphilis, and low complement levels.</p><p class="headingAnchor" id="H2066984739"><span class="h2">Antiphospholipid antibodies</span><span class="headingEndMark"> — </span>The three major aPL tests that are recognized by international classification criteria for antiphospholipid syndrome (APS)  (<a class="graphic graphic_table graphicRef104569" href="/d/graphic/104569.html" rel="external">table 2</a>) are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Anticardiolipin antibodies (aCL) immunoglobulin G (IgG) and/or IgM enzyme-linked immunosorbent assay (ELISA)</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-beta2 glycoprotein (GP) I antibodies IgG and/or IgM ELISA</p><p class="bulletIndent1"><span class="glyph">●</span>Lupus anticoagulant (LA) test</p><p></p><p>Generally, the diagnosis of APS is made in the presence of one or more of the above aPL in the setting of a vascular thrombosis or a specific type of pregnancy morbidity. Individuals with one or more aPL, but without a history of thrombosis, pregnancy complications, or the other clinical manifestations (see <a class="local">'Clinical manifestations'</a> above), may be at risk of developing APS. A detailed discussion on diagnosis of APS is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/4678.html" rel="external">"Diagnosis of antiphospholipid syndrome"</a>.)</p><p>An aPL may be present in some people who do not have APS and are otherwise healthy, who have another autoimmune or rheumatic disease, or who have been exposed to certain drugs or infectious agents. These and other associations are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/4678.html" rel="external">"Diagnosis of antiphospholipid syndrome", section on 'Other conditions associated with antiphospholipid antibodies'</a>.)</p><p>The development of newer tests (antibodies directed against domain I of B2-glycoprotein I or antiphosphatidylserine-prothrombin antibodies) will be useful to identify high-risk APS patients for tailored management [<a href="#rid101">101,102</a>].</p><p class="headingAnchor" id="H2719458857"><span class="h2">Thrombocytopenia</span><span class="headingEndMark"> — </span>Thrombocytopenia can be observed in APS patients, with an incidence ranging from 22 to 42 percent [<a href="#rid61">61</a>]. The frequency of thrombocytopenia is higher in SLE-associated APS than in primary APS. The degree of thrombocytopenia is usually moderate, with a platelet count usually in the range of 100,000 to 140,000/microL, and is rarely associated with hemorrhagic events. Thrombocytopenia is a predictive factor of APS-related manifestations (thrombosis, pregnancy morbidity, hemolytic anemia, or death) [<a href="#rid103">103,104</a>], and a decrease in platelet count frequently preceded an episode of catastrophic APS [<a href="#rid105">105</a>].</p><p class="headingAnchor" id="H2747059528"><span class="h2">Hypocomplementemia</span><span class="headingEndMark"> — </span>Hypocomplementemia can be observed in primary APS, similar to what is observed in patients with SLE [<a href="#rid106">106,107</a>]. As an example, in an observational cohort that included 70 patients with primary APS, nearly half presented with low complement levels [<a href="#rid106">106</a>]. However, complement levels such as C3 and C4 are generally not used to trend disease activity as they are sometimes used in SLE. (See  <a class="medical medical_review" href="/d/html/3930.html" rel="external">"Acquired disorders of the complement system", section on 'Increased consumption by immune complexes'</a>.)</p><p class="headingAnchor" id="H3388124607"><span class="h2">Other</span><span class="headingEndMark"> — </span>Other laboratory abnormalities include the prolongation of a blood coagulation test (eg, aPTT), a hemolytic anemia [<a href="#rid86">86</a>], or a history of a false-positive serologic test for syphilis. (See  <a class="medical medical_review" href="/d/html/4678.html" rel="external">"Diagnosis of antiphospholipid syndrome", section on 'When to suspect the diagnosis'</a>.)</p><p class="headingAnchor" id="H39"><span class="h1">MORTALITY</span><span class="headingEndMark"> — </span>Antiphospholipid syndrome (APS) is associated with increased morbidity and mortality. A large, multicenter, prospective study of 1,000 APS patients found a decreased survival rate of 90.7 percent at 10 years [<a href="#rid11">11</a>]. The main causes of death during the 10-year follow-up included thrombosis (31 percent), sepsis (27 percent), malignancy (14 percent), hemorrhage (11 percent), systemic lupus erythematosus (SLE) involvement (8 percent), and catastrophic APS (5 percent). The mean age at death was 59, with a standard deviation of 14 years. There were no differences in the mortality rates in the presence of underlying disease: 6.8 percent of patients with SLE-associated APS compared with 7.1 percent of patients with primary APS died. Note, however, that during the study period over 40 percent of patients were lost to follow-up.</p><p>The presence of antiphospholipid antibodies (aPL) in the serum of patients with SLE has been identified as an independent risk factor for premature death. This was illustrated in an observational study of 667 patients with SLE, 49 of whom died [<a href="#rid108">108</a>]. There was an increased risk of premature death in patients with aPL, thrombocytopenia, and arterial occlusion. Other factors associated with premature death were the intensity of anticoagulation treatment, renal involvement, pleuritis, and disease activity.</p><p>Although some of the risk of early death is due to the increased propensity to thromboembolic disease, in some settings, aPL may be a marker for a higher mortality rate that is not due to thrombophilia per se. As an example, in a study of 300 consecutive patients with a first ischemic stroke, stroke victims with elevated levels of aPL (immunoglobulin G [IgG] anticardiolipin antibodies [aCL] &gt;20 units) had a higher mortality rate during approximately two years of follow-up than those with lower or absent aCL levels (33 versus 18 percent mortality, relative risk [RR] 1.94, 95% CI 1.05-3.67) [<a href="#rid109">109</a>]. However, the increased mortality was not due to recurrent stroke but was associated with other characteristics of those with aPL, including a higher rate of malignancy and more prevalent risk factors for coronary heart disease.</p><p class="headingAnchor" id="H2686937936"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111936.html" rel="external">"Society guideline links: Antiphospholipid syndrome"</a>.)</p><p class="headingAnchor" id="H40"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/575.html" rel="external">"Patient education: Antiphospholipid syndrome (Beyond the Basics)"</a>).</p><p></p><p class="headingAnchor" id="H41"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Antiphospholipid syndrome (APS) is an autoimmune multisystem disorder characterized by arterial, venous, or small vessel thromboembolic events and/or pregnancy morbidity in the presence of persistent antiphospholipid antibodies (aPL). APS occurs as a primary condition or in the setting of an underlying systemic autoimmune disease, particularly systemic lupus erythematosus (SLE). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiphospholipid antibodies</strong> – The three major aPL tests that are recognized by international classification criteria for APS  (<a class="graphic graphic_table graphicRef104569" href="/d/graphic/104569.html" rel="external">table 2</a>) are anticardiolipin antibodies (aCL) immunoglobulin G (IgG) and/or IgM enzyme-linked immunosorbent assay (ELISA), anti-beta2 glycoprotein (GP) I antibodies IgG and/or IgM ELISA, and the lupus anticoagulant (LA) test. (See <a class="local">'Antiphospholipid antibodies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombotic events</strong> – Thromboses are the hallmark of APS. The deep veins of the lower extremities are the most common sites of venous thrombosis, and the cerebral vasculature (stroke and transient ischemic attack) is the most common site for arterial thrombosis. Superficial vein thrombosis can also occur. (See <a class="local">'Thrombotic events'</a> above and <a class="local">'Neurologic involvement'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neurologic involvement</strong> – Stroke and transient ischemic attack are the most common neurologic manifestations of APS. Cognitive deficits independent of stroke and/or white matter lesions have also been associated with APS. (See <a class="local">'Neurologic involvement'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hematologic abnormalities</strong> – Thrombocytopenia can be observed in APS, but the degree is usually moderate and is rarely associated with hemorrhagic events. Other hematologic abnormalities reported with APS include various thrombotic microangiopathy (TMA) syndromes and autoimmune hemolytic anemia. (See <a class="local">'Hematologic abnormalities'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pulmonary involvement</strong> – Patients with APS may develop various lung manifestations including pulmonary thromboembolic disease, thromboembolic and non-thromboembolic pulmonary hypertension (pulmonary arterial hypertension), pulmonary arterial thrombosis, pulmonary microthrombosis, acute respiratory distress syndrome, and diffuse alveolar hemorrhage. (See <a class="local">'Pulmonary involvement'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac involvement</strong> – Cardiac manifestations of APS most commonly involve the valves, including valvular thickening, and valve nodules (also referred to as nonbacterial vegetations or Libman-Sacks endocarditis), which can lead to valvular dysfunction. (See <a class="local">'Cardiac involvement'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cutaneous manifestations</strong> – Livedo  (<a class="graphic graphic_picture graphicRef67495" href="/d/graphic/67495.html" rel="external">picture 2</a>) is the most common cutaneous manifestation of APS; while livedo reticularis is also relatively common in the general population, livedo racemosa is more specific for APS. Other cutaneous abnormalities that can occur in APS patients include splinter hemorrhages, cutaneous necrosis and infarction, digital gangrene, skin ulcerations, lesions resembling vasculitis ("pseudovasculitic" nodules, macules), and livedoid vasculopathy. (See <a class="local">'Cutaneous manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other manifestations</strong> – Other less common manifestations of APS include ocular involvement, renal disease, adrenal insufficiency, and gastrointestinal involvement. (See <a class="local">'Ocular involvement'</a> above and <a class="local">'Kidney disease'</a> above and <a class="local">'Adrenal disease'</a> above and <a class="local">'Gastrointestinal involvement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy complications</strong> – Pregnancy complications are another hallmark of APS. These complications include fetal death after 10 weeks gestation, premature birth due to severe preeclampsia or placental insufficiency, and/or multiple embryonic losses (&lt;10 weeks gestation). (See <a class="local">'Pregnancy complications'</a> above and  <a class="medical medical_review" href="/d/html/6813.html" rel="external">"Antiphospholipid syndrome: Obstetric implications and management in pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Catastrophic APS</strong> – Rarely, patients with APS can develop catastrophic APS (CAPS), with widespread thrombotic disease and multiorgan failure  (<a class="graphic graphic_table graphicRef62724" href="/d/graphic/62724.html" rel="external">table 1</a>). CAPS can also rarely be the initial presentation of APS. (See  <a class="medical medical_review" href="/d/html/106168.html" rel="external">"Catastrophic antiphospholipid syndrome (CAPS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – APS is associated with increased morbidity and mortality. Major causes of death include thrombosis, sepsis, malignancy, hemorrhage, SLE involvement, and catastrophic APS. (See <a class="local">'Mortality'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295.</a></li><li><a class="nounderline abstract_t">Andreoli L, Chighizola CB, Banzato A, et al. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken) 2013; 65:1869.</a></li><li><a class="nounderline abstract_t">Macklon NS, Geraedts JP, Fauser BC. Conception to ongoing pregnancy: the 'black box' of early pregnancy loss. Hum Reprod Update 2002; 8:333.</a></li><li><a class="nounderline abstract_t">Stephenson MD. Frequency of factors associated with habitual abortion in 197 couples. Fertil Steril 1996; 66:24.</a></li><li><a class="nounderline abstract_t">Martin JA, Hamilton BE, Ventura SJ, et al. Births: final data for 2009. Natl Vital Stat Rep 2011; 60:1.</a></li><li><a class="nounderline abstract_t">Roger VL, Go AS, Lloyd-Jones DM, et al. Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation 2012; 125:188.</a></li><li><a class="nounderline abstract_t">White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107:I4.</a></li><li class="breakAll">www.census.gov/population/www/cen2010/glance/index.html (Accessed on October 19, 2015).</li><li><a class="nounderline abstract_t">Duarte-García A, Crowson CS, Warrington KJ, Matteson EL. Reply. Arthritis Rheumatol 2020; 72:1776.</a></li><li><a class="nounderline abstract_t">Radin M, Sciascia S, Bazzan M, et al. Antiphospholipid Syndrome Is Still a Rare Disease-Estimated Prevalence in the Piedmont and Aosta Valley Regions of Northwest Italy: Comment on the Article by Duarte-García et al. Arthritis Rheumatol 2020; 72:1774.</a></li><li><a class="nounderline abstract_t">Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015; 74:1011.</a></li><li><a class="nounderline abstract_t">Vianna JL, Khamashta MA, Ordi-Ros J, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med 1994; 96:3.</a></li><li><a class="nounderline abstract_t">Djokovic A, Stojanovich L, Kontic M, et al. Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome. Isr Med Assoc J 2014; 16:162.</a></li><li><a class="nounderline abstract_t">Cervera R, Boffa MC, Khamashta MA, Hughes GR. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009; 18:889.</a></li><li><a class="nounderline abstract_t">Unlu O, Erkan D, Barbhaiya M, et al. The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. Arthritis Care Res (Hoboken) 2019; 71:134.</a></li><li><a class="nounderline abstract_t">Danowski A, de Azevedo MN, de Souza Papi JA, Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009; 36:1195.</a></li><li><a class="nounderline abstract_t">Ribeiro AR, Carvalho JF. [Traditional risk factors for cardiovascular disease in primary antiphospholipid syndrome (APS) when compared with secondary APS: a study with 96 patients]. Acta Reumatol Port 2010; 35:36.</a></li><li><a class="nounderline abstract_t">Belizna CC, Richard V, Primard E, et al. Early atheroma in primary and secondary antiphospholipid syndrome: an intrinsic finding. Semin Arthritis Rheum 2008; 37:373.</a></li><li><a class="nounderline abstract_t">Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994; 84:2854.</a></li><li><a class="nounderline abstract_t">Mujic F, Cuadrado MJ, Lloyd M, et al. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. J Rheumatol 1995; 22:1589.</a></li><li><a class="nounderline abstract_t">Gómez-Puerta JA, Martín H, Amigo MC, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore) 2005; 84:225.</a></li><li><a class="nounderline abstract_t">Veres K, Szodoray P, Szekanecz Z, et al. Clinical and immunoserological characteristics of the transition from primary to overlap antiphospholipid syndrome. Lupus 2010; 19:1520.</a></li><li><a class="nounderline abstract_t">Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376:1498.</a></li><li><a class="nounderline abstract_t">Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46:1019.</a></li><li><a class="nounderline abstract_t">Zuily S, Clerc-Urmès I, Bauman C, et al. Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. Lupus 2020; 29:1353.</a></li><li><a class="nounderline abstract_t">Tektonidou MG, Varsou N, Kotoulas G, et al. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med 2006; 166:2278.</a></li><li><a class="nounderline abstract_t">Sanna G, Bertolaccini ML, Khamashta MA. Unusual clinical manifestations of the antiphospholipid syndrome. Current Rheumatology Reviews 2006; 2:387.</a></li><li><a class="nounderline abstract_t">Abreu MM, Danowski A, Wahl DG, et al. The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015; 14:401.</a></li><li><a class="nounderline abstract_t">Meroni PL, Chighizola CB, Rovelli F, Gerosa M. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther 2014; 16:209.</a></li><li><a class="nounderline abstract_t">Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101:1827.</a></li><li><a class="nounderline abstract_t">Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8:237.</a></li><li><a class="nounderline abstract_t">Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009; 68:1428.</a></li><li><a class="nounderline abstract_t">Zuily S, Regnault V, Guillemin F, et al. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study. Thromb Res 2013; 132:e1.</a></li><li><a class="nounderline abstract_t">Schmidt-Tanguy A, Voswinkel J, Henrion D, et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost 2013; 11:1927.</a></li><li><a class="nounderline abstract_t">Wittkowsky AK, Downing J, Blackburn J, Nutescu E. Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. Thromb Haemost 2006; 96:137.</a></li><li><a class="nounderline abstract_t">Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3:1231.</a></li><li><a class="nounderline abstract_t">Kearon C, Parpia S, Spencer FA, et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood 2018; 131:2151.</a></li><li><a class="nounderline abstract_t">Pengo V, Biasiolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93:1147.</a></li><li><a class="nounderline abstract_t">Ruffatti A, Tonello M, Del Ross T, et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006; 96:337.</a></li><li><a class="nounderline abstract_t">Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117:303.</a></li><li><a class="nounderline abstract_t">Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100:530.</a></li><li><a class="nounderline abstract_t">Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332:993.</a></li><li><a class="nounderline abstract_t">Arnson Y, Shoenfeld Y, Alon E, Amital H. The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum 2010; 40:97.</a></li><li><a class="nounderline abstract_t">Francès C, Piette JC. The mystery of Sneddon syndrome: relationship with antiphospholipid syndrome and systemic lupus erythematosus. J Autoimmun 2000; 15:139.</a></li><li><a class="nounderline abstract_t">Hilton DA, Footitt D. Neuropathological findings in Sneddon's syndrome. Neurology 2003; 60:1181.</a></li><li><a class="nounderline abstract_t">Muscal E, Brey RL. Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons. Curr Rheumatol Rep 2008; 10:67.</a></li><li><a class="nounderline abstract_t">Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30:985.</a></li><li><a class="nounderline abstract_t">Cuadrado MJ, Khamashta MA, Ballesteros A, et al. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore) 2000; 79:57.</a></li><li><a class="nounderline abstract_t">Theodoridou A, Settas L. Demyelination in rheumatic diseases. J Neurol Neurosurg Psychiatry 2006; 77:290.</a></li><li><a class="nounderline abstract_t">Avcin T, Cimaz R, Meroni PL. Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations. Lupus 2002; 11:4.</a></li><li><a class="nounderline abstract_t">Shoenfeld Y, Lev S, Blatt I, et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol 2004; 31:1344.</a></li><li><a class="nounderline abstract_t">Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 2003; 42:200.</a></li><li><a class="nounderline abstract_t">Asherson RA, Mercey D, Phillips G, et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 1987; 46:605.</a></li><li><a class="nounderline abstract_t">Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer &gt; 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997; 28:1660.</a></li><li><a class="nounderline abstract_t">Herranz MT, Rivier G, Khamashta MA, et al. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37:568.</a></li><li><a class="nounderline abstract_t">Cervera R, Asherson RA, Font J, et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 1997; 76:203.</a></li><li><a class="nounderline abstract_t">Verrot D, San-Marco M, Dravet C, et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997; 103:33.</a></li><li><a class="nounderline abstract_t">Kandiah DA, Sali A, Sheng Y, et al. Current insights into the "antiphospholipid" syndrome: clinical, immunological, and molecular aspects. Adv Immunol 1998; 70:507.</a></li><li><a class="nounderline abstract_t">Mouadeb DA, Ruckenstein MJ. Antiphospholipid inner ear syndrome. Laryngoscope 2005; 115:879.</a></li><li><a class="nounderline abstract_t">Chapman J, Rand JH, Brey RL, et al. Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus 2003; 12:514.</a></li><li><a class="nounderline abstract_t">Uthman I, Godeau B, Taher A, Khamashta M. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev 2008; 22:187.</a></li><li><a class="nounderline abstract_t">Zuily S, Domingues V, Suty-Selton C, et al. Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: A systematic review and meta-analysis. Autoimmun Rev 2017; 16:576.</a></li><li><a class="nounderline abstract_t">Rosen K, Raanani E, Kogan A, et al. Chronic thromboembolic pulmonary hypertension in patients with antiphospholipid syndrome: Risk factors and management. J Heart Lung Transplant 2022; 41:208.</a></li><li><a class="nounderline abstract_t">Espinosa G, Cervera R, Font J, Asherson RA. The lung in the antiphospholipid syndrome. Ann Rheum Dis 2002; 61:195.</a></li><li><a class="nounderline abstract_t">Asherson RA, Higenbottam TW, Dinh Xuan AT, et al. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 1990; 17:1292.</a></li><li><a class="nounderline abstract_t">Deane KD, West SG. Antiphospholipid antibodies as a cause of pulmonary capillaritis and diffuse alveolar hemorrhage: a case series and literature review. Semin Arthritis Rheum 2005; 35:154.</a></li><li><a class="nounderline abstract_t">Asherson RA, Cervera R. Review: antiphospholipid antibodies and the lung. J Rheumatol 1995; 22:62.</a></li><li><a class="nounderline abstract_t">Kanakis MA, Kapsimali V, Vaiopoulos AG, et al. The lung in the spectrum of antiphospholipid syndrome. Clin Exp Rheumatol 2013; 31:452.</a></li><li><a class="nounderline abstract_t">Zuily S, Wahl D. Pulmonary hypertension in antiphospholipid syndrome. Curr Rheumatol Rep 2015; 17:478.</a></li><li><a class="nounderline abstract_t">Denas G, Jose SP, Bracco A, et al. Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun Rev 2015; 14:214.</a></li><li><a class="nounderline abstract_t">Jouhikainen T, Pohjola-Sintonen S, Stephansson E. Lupus anticoagulant and cardiac manifestations in systemic lupus erythematosus. Lupus 1994; 3:167.</a></li><li><a class="nounderline abstract_t">Espínola-Zavaleta N, Vargas-Barrón J, Colmenares-Galvis T, et al. Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am Heart J 1999; 137:973.</a></li><li><a class="nounderline abstract_t">Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996; 93:1579.</a></li><li><a class="nounderline abstract_t">Turiel M, Sarzi-Puttini P, Peretti R, et al. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol 2005; 96:574.</a></li><li><a class="nounderline abstract_t">Farzaneh-Far A, Roman MJ, Lockshin MD, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum 2006; 54:3918.</a></li><li><a class="nounderline abstract_t">Zuily S, Huttin O, Mohamed S, et al. Valvular heart disease in antiphospholipid syndrome. Curr Rheumatol Rep 2013; 15:320.</a></li><li><a class="nounderline abstract_t">Roldan CA, Gelgand EA, Qualls CR, Sibbitt WL Jr. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol 2005; 95:1441.</a></li><li><a class="nounderline abstract_t">Roldan CA, Gelgand EA, Qualls CR, Sibbitt WL Jr. Valvular heart disease by transthoracic echocardiography is associated with focal brain injury and central neuropsychiatric systemic lupus erythematosus. Cardiology 2007; 108:331.</a></li><li><a class="nounderline abstract_t">Zuily S, Regnault V, Selton-Suty C, et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation 2011; 124:215.</a></li><li><a class="nounderline abstract_t">Chighizola CB, Andreoli L, de Jesus GR, et al. The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Lupus 2015; 24:980.</a></li><li><a class="nounderline abstract_t">Gibson GE, Su WP, Pittelkow MR. Antiphospholipid syndrome and the skin. J Am Acad Dermatol 1997; 36:970.</a></li><li><a class="nounderline abstract_t">Francès C, Niang S, Laffitte E, et al. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum 2005; 52:1785.</a></li><li><a class="nounderline abstract_t">Hairston BR, Davis MD, Pittelkow MR, Ahmed I. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol 2006; 142:1413.</a></li><li><a class="nounderline abstract_t">Mostafa M, Mahmoud A, Egiza HA, et al. Severe cutaneous necrosis in antiphospholipid syndrome. Am J Hematol 2023; 98:E328.</a></li><li><a class="nounderline abstract_t">Toubi E, Krause I, Fraser A, et al. Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol 2005; 23:499.</a></li><li><a class="nounderline abstract_t">Ünlü O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol 2016; 3:75.</a></li><li><a class="nounderline abstract_t">Uthman IW, Khamashta MA. Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome. J Rheumatol 2006; 33:2379.</a></li><li><a class="nounderline abstract_t">Kawakami T, Yamazaki M, Mizoguchi M, Soma Y. Differences in anti-phosphatidylserine-prothrombin complex antibodies and cutaneous vasculitis between regular livedo reticularis and livedo racemosa. Rheumatology (Oxford) 2009; 48:508.</a></li><li><a class="nounderline abstract_t">Ehrmann S. Ein Gefaessprozess Bei Lues. Wien Med Wochenschr 1907; 57:777.</a></li><li><a class="nounderline abstract_t">Gibbs MB, English JC 3rd, Zirwas MJ. Livedo reticularis: an update. J Am Acad Dermatol 2005; 52:1009.</a></li><li><a class="nounderline abstract_t">Uthman I, Khamashta M. The abdominal manifestations of the antiphospholipid syndrome. Rheumatology (Oxford) 2007; 46:1641.</a></li><li><a class="nounderline abstract_t">Qi X, De Stefano V, Su C, et al. Associations of antiphospholipid antibodies with splanchnic vein thrombosis: a systematic review with meta-analysis. Medicine (Baltimore) 2015; 94:e496.</a></li><li><a class="nounderline abstract_t">Zhu W, Wu Y, Xu M, et al. Antiphospholipid antibody and risk of retinal vein occlusion: a systematic review and meta-analysis. PLoS One 2014; 10:e0122814.</a></li><li><a class="nounderline abstract_t">Miserocchi E, Baltatzis S, Foster CS. Ocular features associated with anticardiolipin antibodies: a descriptive study. Am J Ophthalmol 2001; 131:451.</a></li><li><a class="nounderline abstract_t">Carbone J, Sánchez-Ramón S, Cobo-Soriano R, et al. Antiphospholipid antibodies: a risk factor for occlusive retinal vascular disorders. Comparison with ocular inflammatory diseases. J Rheumatol 2001; 28:2437.</a></li><li><a class="nounderline abstract_t">Espinosa G, Santos E, Cervera R, et al. Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients. Medicine (Baltimore) 2003; 82:106.</a></li><li><a class="nounderline abstract_t">Ramon I, Mathian A, Bachelot A, et al. Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in the antiphospholipid syndrome: long-term outcome of 16 patients. J Clin Endocrinol Metab 2013; 98:3179.</a></li><li><a class="nounderline abstract_t">Tektonidou MG, Malagari K, Vlachoyiannopoulos PG, et al. Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. Arthritis Rheum 2003; 48:732.</a></li><li><a class="nounderline abstract_t">Gómez-Puerta JA, Cervera R, Espinosa G, et al. Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis 2007; 66:740.</a></li><li><a class="nounderline abstract_t">Hanouna G, Morel N, Le Thi Huong D, et al. Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases. Rheumatology (Oxford) 2013; 52:1635.</a></li><li><a class="nounderline abstract_t">Zuily S, de Laat B, Guillemin F, et al. Anti-Domain I β2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study. J Appl Lab Med 2020; 5:1242.</a></li><li><a class="nounderline abstract_t">Zuily S, de Laat B, Mohamed S, et al. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Rheumatology (Oxford) 2015; 54:2071.</a></li><li><a class="nounderline abstract_t">Moulinet T, Dufrost V, Clerc-Urmès I, et al. Risk of thrombosis, pregnancy morbidity or death in antiphospholipid antibodies positive patients with or without thrombocytopenia. Eur J Intern Med 2021; 84:101.</a></li><li><a class="nounderline abstract_t">Shi Y, Zhao J, Jiang H, et al. Thrombocytopenia in primary antiphospholipid syndrome: association with prognosis and clinical implications. Rheumatology (Oxford) 2022; 62:256.</a></li><li><a class="nounderline abstract_t">Pontara E, Banzato A, Bison E, et al. Thrombocytopenia in high-risk patients with antiphospholipid syndrome. J Thromb Haemost 2018; 16:529.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Campoamor MT, Chamorro A, et al. Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus 2004; 13:777.</a></li><li><a class="nounderline abstract_t">Oku K, Atsumi T, Bohgaki M, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009; 68:1030.</a></li><li><a class="nounderline abstract_t">Drenkard C, Villa AR, Alarcón-Segovia D, Pérez-Vázquez ME. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol 1994; 21:1067.</a></li><li><a class="nounderline abstract_t">Tanne D, D'Olhaberriague L, Trivedi AM, et al. Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. Neuroepidemiology 2002; 21:93.</a></li></ol></div><div id="topicVersionRevision">Topic 4667 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16420554" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23861221" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12206468" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Conception to ongoing pregnancy: the 'black box' of early pregnancy loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8752606" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Frequency of factors associated with habitual abortion in 197 couples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22670489" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Births: final data for 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22215894" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12814979" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The epidemiology of venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12814979" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The epidemiology of venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32869535" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Reply.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32840055" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Antiphospholipid Syndrome Is Still a Rare Disease-Estimated Prevalence in the Piedmont and Aosta Valley Regions of Northwest Italy: Comment on the Article by Duarte-García et al.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24464962" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8304360" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24761704" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19671788" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29669399" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19447935" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20505627" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : [Traditional risk factors for cardiovascular disease in primary antiphospholipid syndrome (APS) when compared with secondary APS: a study with 96 patients].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17977581" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Early atheroma in primary and secondary antiphospholipid syndrome: an intrinsic finding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7949161" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7473490" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Primary antiphospholipid syndrome evolving into systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16010207" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20685773" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical and immunoserological characteristics of the transition from primary to overlap antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20822807" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11953980" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32703117" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17101948" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Unusual clinical manifestations of the antiphospholipid syndrome</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25641203" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25166960" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393574" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19874470" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18801761" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23676348" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23902281" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16894455" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15946213" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29490924" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15968401" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Antibody profiles for the diagnosis of antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16953276" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1637025" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8644765" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7885428" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The management of thrombosis in the antiphospholipid-antibody syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19596138" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The antiphospholipid syndrome as a neurological disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10968900" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The mystery of Sneddon syndrome: relationship with antiphospholipid syndrome and systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12682330" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Neuropathological findings in Sneddon's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18457615" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12734893" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10670410" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16484634" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Demyelination in rheumatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11898917" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15229954" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Features associated with epilepsy in the antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12595612" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Central nervous system involvement in the antiphospholipid (Hughes) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3116954" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9303006" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : IgG anticardiolipin antibody titer&gt;40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8147935" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9193455" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9236483" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9755344" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Current insights into the "antiphospholipid" syndrome: clinical, immunological, and molecular aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15867658" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Antiphospholipid inner ear syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12892390" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18417261" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The hematologic manifestations of the antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28411166" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34836752" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Chronic thromboembolic pulmonary hypertension in patients with antiphospholipid syndrome: Risk factors and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11830421" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The lung in the antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2123932" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pulmonary hypertension in a lupus clinic: experience with twenty-four patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16325656" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Antiphospholipid antibodies as a cause of pulmonary capillaritis and diffuse alveolar hemorrhage: a case series and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7699684" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Review: antiphospholipid antibodies and the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23415021" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The lung in the spectrum of antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25604574" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pulmonary hypertension in antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25461836" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Antiphospholipid syndrome and the heart: a case series and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7951302" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Lupus anticoagulant and cardiac manifestations in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10220649" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Echocardiographic evaluation of patients with primary antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8608627" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098314" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133599" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23456852" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Valvular heart disease in antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15950567" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299260" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Valvular heart disease by transthoracic echocardiography is associated with focal brain injury and central neuropsychiatric systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21690492" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25697769" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9204065" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Antiphospholipid syndrome and the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15934071" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116831" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Livedoid vasculopathy: further evidence for procoagulant pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37713504" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Severe cutaneous necrosis in antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16095119" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27708976" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17143977" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19273539" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Differences in anti-phosphatidylserine-prothrombin complex antibodies and cutaneous vasculitis between regular livedo reticularis and livedo racemosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Ein Gefaessprozess Bei Lues</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15928620" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Livedo reticularis: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636180" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The abdominal manifestations of the antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25634200" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Associations of antiphospholipid antibodies with splanchnic vein thrombosis: a systematic review with meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25918850" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Antiphospholipid antibody and risk of retinal vein occlusion: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11292408" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Ocular features associated with anticardiolipin antibodies: a descriptive study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11708415" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Antiphospholipid antibodies: a risk factor for occlusive retinal vascular disorders. Comparison with ocular inflammatory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12640187" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23783099" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in the antiphospholipid syndrome: long-term outcome of 16 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12632427" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17223653" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23676524" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32572467" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Anti-Domain Iβ2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26163690" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33082035" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Risk of thrombosis, pregnancy morbidity or death in antiphospholipid antibodies positive patients with or without thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35536236" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Thrombocytopenia in primary antiphospholipid syndrome: association with prognosis and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29316193" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Thrombocytopenia in high-risk patients with antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15540510" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18625630" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Complement activation in patients with primary antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7932417" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11901279" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
